Gilead Sciences, Inc. GILD announced positive data on breast cancer drug Trodelvy (sacituzumab govitecan-hziy) from the late-stage ASCENT-04/KEYNOTE-D19 study.

Gilead's (GILD) Trodelvy with Merck's (MRK) Keytruda shows a 35% reduced risk of disease progression or death against a type of aggressive breast cancer. Read more here.

FOSTER CITY, Calif. -- (BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD) today announced Trodelvy ® (sacituzumab govitecan-hziy) plus Keytruda ® (pembrolizumab) reduced the risk of disease ...

$79.09 0.33 % Gilead Sciences, Inc. GILD on Monday released topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study of Trodelvy (sacituzumab govitecan-hziy) plus Merck & Co Inc’s MRK ...

But Gilead has encountered setbacks in its efforts to expand the drug’s label. At the beginning of this year, Gilead reported Trodelvy failed a Phase 3 test in non-small cell lung cancer.

Oncology: Gilead has established a strong presence in the oncology market, developing therapies like Trodelvy, which targets specific cancer types and shows promise for expanding its reach in the ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ASCENT-04/KEYNOTE-D19 study, demonstrating that Trodelvy ® (sacituzumab govitecan-hziy) plus ...

FOSTER CITY, Calif.-- (BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ASCENT-03 study of Trodelvy® (sacituzumab govitecan-hziy ...

However, Gilead’s efforts to expand Trodelvy’s label suffered a setback due to the failure of its late-stage confirmatory TROPiCS-04 study on Trodelvy in locally advanced or metastatic ...

Sacituzumab govitecan-hziv (Trodelvy, Gilead Sciences) is a TROP-2-directed antibody-drug conjugate. The FDA granted accelerated approval for the urothelial cancer indication in 2021.

(RTTNews) - Gilead Sciences, Inc. (GILD) Friday announced positive topline results from the Phase 3 ASCENT-03 study of Trodelvy in patients with first-line metastatic triple-negative breast cancer ...

Gilead has made the decision to withdraw the accelerated approval of Trodelvy ® (sacituzumab govitecan-hziy) for metastatic urothelial cancer in the US. Trodelvy, a Trop-2-directed antibody and ...